论文部分内容阅读
目的:对肺结核患者给予利福喷丁与利福平进行治疗的临床效果加以分析。方法:选择2015年8月-2016年8月中我院感染科收治的80例肺结核患者作为研究对象,根据抽签的方式将患者分成两组,即参照组40例患者,给予其利福平药物进行治疗,实验组则有40例患者,给予其利福喷丁药物进行治疗。对比分析两组患者的治疗效果。结果:对比两组患者的治疗有效率得知,实验组患者的治疗有效率为95.00%,参照组的仅为72.50%,同时实验组发生不良反应的例数有5例,发生率为12.50%;参照组发生不良反应的有13例,发生率高达32.50%,组间差异性显著,且P<0.05,呈现临床不均衡性。结论:实验组患者采用利福喷丁对肺结核进行治疗,其临床效果明显,不但能够有效提升患者的治愈率,同时也能够显著减少不良反应的发生率,值得临床推广和应用。
OBJECTIVE: To analyze the clinical effects of rifapentine and rifampicin in patients with pulmonary tuberculosis. Methods: From August 2015 to August 2016, 80 patients with pulmonary tuberculosis admitted to our department were divided into two groups according to the way of drawing lots, namely 40 patients in the reference group and given rifampicin For treatment, 40 patients in the experimental group were given rifapentine for treatment. Comparative analysis of two groups of patients treatment. Results: Compared with the two groups of patients, the effective rate of treatment was 95.00% in the experimental group and 72.50% in the reference group. There were 5 cases of adverse reactions in the experimental group, the incidence rate was 12.50% ; 13 cases of adverse reactions in the reference group, the incidence was as high as 32.50%, significant difference between groups, and P <0.05, showing clinical imbalance. Conclusion: The experimental group treated with rifapentin for pulmonary tuberculosis, the clinical effect is obvious, not only can effectively improve the cure rate of patients, but also can significantly reduce the incidence of adverse reactions, is worthy of clinical promotion and application.